Leta i den här bloggen


torsdag 7 mars 2024

AGO2 ja Rintasyöpä, onko assosiaatiota= HAKU PubMed 7.3. 2024

 

71 results

Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer.
Casey MC, Prakash A, Holian E, McGuire A, Kalinina O, Shalaby A, Curran C, Webber M, Callagy G, Bourke E, Kerin MJ, Brown JA. BMC Cancer. 2019 Jul 19;19(1):712. doi: 10.1186/s12885-019-5884-x. PMID: 31324173 Free PMC article.
However Ago2 expression and localisation in breast cancer remains undetermined. ...CONCLUSIONS: Quantification of Ago2 improves the stratification of breast cancer and suggests a differential role for Ago2 in breast cance
The CXCR4-Dependent LASP1-Ago2 Interaction in Triple-Negative Breast Cancer.
Tilley AMC, Howard CM, Sridharan S, Subramaniyan B, Bearss NR, Alkhalili S, Raman D. Cancers (Basel). 2020 Aug 29;12(9):2455. doi: 10.3390/cancers12092455. PMID: 32872485 Free PMC article.
The CXCR4-LASP1 axis is an emerging target in the field of breast cancer metastasis. C-X-C chemokine receptor type 4 (CXCR4) mediates directed cell migration when activated by its cognate ligand CXCL12. ...Our previous proteomics work had revealed several components …
Treatment of breast cancer with autophagy inhibitory microRNAs carried by AGO2-conjugated nanoparticles.
Unal O, Akkoc Y, Kocak M, Nalbat E, Dogan-Ekici AI, Yagci Acar H, Gozuacik D. J Nanobiotechnology. 2020 Apr 28;18(1):65. doi: 10.1186/s12951-020-00615-4. PMID: 32345308 Free PMC article.
These functionalized nanoparticles selectively delivered an effective amount of the microRNA into HER2-positive breast cancer cell lines in vitro and in a xenograft nude mice model of breast cancer in vivo, and successfully blocked autophagy. ...Theref …
Presence of anti-TIF-1gamma, anti-Ro52, anti-SSA/Ro60 and anti-Su/Ago2 antibodies in breast cancer: a cross-sectional study.
Vázquez-Del Mercado M, Martínez-García EA, Daneri-Navarro A, Gómez-Bañuelos E, Martín-Márquez BT, Pizano-Martínez O, Wilson-Manríquez EA, Corona-Sánchez EG, Chavarria-Avila E, Sandoval-García F, Satoh M. Immunopharmacol Immunotoxicol. 2021 Jun;43(3):328-333. doi: 10.1080/08923973.2021.1910833. Epub 2021 Apr 20. PMID: 33876712 Clinical Trial.
As a whole, 14.47% (22/152) of breast cancer patients showed autoantibodies associated with SARD. ...CONCLUSIONS: Autoantibodies to TIF-1gamma were found in two patients with breast cancer without dermatomyositis (DM). More common specificities were au …
MiRNAs Overexpression and Their Role in Breast Cancer: Implications for Cancer Therapeutics.
Lee SH, Ng CX, Wong SR, Chong PP. Curr Drug Targets. 2023;24(6):484-508. doi: 10.2174/1389450124666230329123409. PMID: 36999414 Review.
This review focuses on the role and mechanisms of miRNAs in different stages of breast cancer progression, including breast cancer stem cell formation, breast cancer initiation, invasion, and metastasis as well as angiogenesis. ...Althoug …
RNA interference: Promising approach for breast cancer diagnosis and treatment.
Allahyari E, Velaei K, Sanaat Z, Jalilzadeh N, Mehdizadeh A, Rahmati M. Cell Biol Int. 2023 May;47(5):833-847. doi: 10.1002/cbin.11979. Epub 2022 Dec 26. PMID: 36571107 Review.
Today, cancer is one of the main health-related challenges, and in the meantime, breast cancer (BC) is one of the most common cancers among women, with an alarming number of incidences and deaths every year. ...After transcription and edition, these two nonco …
Pristimerin Suppressed Breast Cancer Progression via miR-542-5p/DUB3 Axis.
Cheng S, Zhang Z, Hu C, Xing N, Xia Y, Pang B. Onco Targets Ther. 2020 Jul 7;13:6651-6660. doi: 10.2147/OTT.S257329. eCollection 2020. PMID: 32753899 Free PMC article.
BACKGROUND: Breast cancer is one of the most common and malignant tumors in the world. ...MATERIALS AND METHODS: Breast cancer cell lines MCF-7, MDA-MB-231, and 4T1 were used. Cell Counting Kit-8 (CCK-8) assay was performed to evaluate proliferation vi …
miRNA-dependent regulation of STIM1 expression in breast cancer.
Kulkarni RP, Elmi A, Alcantara-Adap E, Hubrack S, Nader N, Yu F, Dib M, Ramachandran V, Najafi Shoushtari H, Machaca K. Sci Rep. 2019 Sep 10;9(1):13076. doi: 10.1038/s41598-019-49629-5. PMID: 31506588 Free PMC article.
Clinically, STIM1 and Ago2 expression levels do not correlate with breast cancer progression, however in the basal subtype high STIM1 expression is associated with poorer survival. Our findings show that STIM1 expression is differentially regulated by the miR …
Inhibitory Effects of Ursolic Acid on the Stemness and Progression of Human Breast Cancer Cells by Modulating Argonaute-2.
Liao WL, Liu YF, Ying TH, Shieh JC, Hung YT, Lee HJ, Shen CY, Cheng CW. Int J Mol Sci. 2022 Dec 26;24(1):366. doi: 10.3390/ijms24010366. PMID: 36613808 Free PMC article.
Furthermore, the co-reduction in oncogenic miRNA levels (miR-9 and miR-221) was a result of the down-modulation in AGO2 in breast cancer cells in vitro. Mechanically, UA increases PTEN expression to inactivate the FAK/PI3K/Akt/mTOR signaling pathway and the d …
Sequestosome 1 (p62) accumulation in breast cancer cells suppresses progesterone receptor expression via argonaute 2.
Yokota A, Hiramoto M, Hino H, Tokuhisa M, Miyazaki M, Kazama H, Takano N, Miyazawa K. Biochem Biophys Res Commun. 2020 Oct 15;531(2):256-263. doi: 10.1016/j.bbrc.2020.07.058. Epub 2020 Aug 13. PMID: 32800344
However, the role of p62 in the breast cancer pathophysiology is still unclear. Here, we aimed to analyze the effect of changes in p62 expression on breast cancer cell lines. ...Moreover, the p62-AGO2-PR axis was identified as a crucial signalin …

Inga kommentarer:

Skicka en kommentar